RU2328489C3 - Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения - Google Patents
Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее полученияInfo
- Publication number
- RU2328489C3 RU2328489C3 RU2006126977A RU2006126977A RU2328489C3 RU 2328489 C3 RU2328489 C3 RU 2328489C3 RU 2006126977 A RU2006126977 A RU 2006126977A RU 2006126977 A RU2006126977 A RU 2006126977A RU 2328489 C3 RU2328489 C3 RU 2328489C3
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- crystalline form
- aminophenoxy
- chloro
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Claims (9)
1. Кристаллическая форма метансульфоната 4-(3-хлор-4-(циклопропиламинокарбонил)-аминофенокси)-7-метокси-6-хинолинкарбоксамида (форма С), имеющая дифракционные пики при углах отклонения при дифракции (2θ ±0,2°) 14,20 и 17,59° в порошковой рентгенограмме.
2. Кристаллическая форма метансульфоната 4-(3-хлор-4-(циклопропиламинокарбонил)-аминофенокси)-7-метокси-6-хинолинкарбоксамида (форма С), имеющая пики при химических сдвигах примерно 160,2 м.д., примерно 126,6 м.д., примерно 105,6 м.д. и примерно 7,8 м.д. в спектре 13С-Ядерного Магнитного Резонанса в твердом состоянии.
3. Кристаллическая форма метансульфоната 4-(3-хлор-4-(циклопропиламинокарбонил)-аминофенокси)-7-метокси-6-хинолинкарбоксамида (форма С), имеющая полосы поглощения при волновых числах 1324±1 и 579±1 см-1 в инфракрасном спектре поглощения.
4. Фармацевтическая композиция, обладающая активностью в отношении ангиогенеза, содержащая кристаллическую форму по любому из пп.1-3.
5. Фармацевтическая композиция по п.4, представляющая собой агент для профилактики или лечения заболевания, при котором является эффективным ингибирование ангиогенеза.
6. Фармацевтическая композиция по п.4, представляющая собой ингибитор ангиогенеза.
7. Фармацевтическая композиция по п.4, представляющая собой противоопухолевый агент.
8. Фармацевтическая композиция по п.7, где опухолью является почечный рак.
9. Фармацевтическая композиция по п.7, представляющая собой ингибитор метастазирования рака.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-430939 | 2003-12-25 | ||
| JP2003430939 | 2003-12-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2006126977A RU2006126977A (ru) | 2008-01-27 |
| RU2328489C2 RU2328489C2 (ru) | 2008-07-10 |
| RU2328489C3 true RU2328489C3 (ru) | 2018-06-01 |
Family
ID=34736366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006126977A RU2328489C3 (ru) | 2003-12-25 | 2004-12-22 | Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7612208B2 (ru) |
| EP (2) | EP2567955A3 (ru) |
| JP (2) | JP4648835B2 (ru) |
| KR (3) | KR100839554B1 (ru) |
| CN (4) | CN101337932B (ru) |
| AU (1) | AU2004309217B2 (ru) |
| BR (1) | BRPI0418200A (ru) |
| CA (1) | CA2543650C (ru) |
| CY (1) | CY1116312T1 (ru) |
| DK (1) | DK1698623T3 (ru) |
| ES (1) | ES2540852T3 (ru) |
| HR (1) | HRP20150694T1 (ru) |
| HU (1) | HUE025742T2 (ru) |
| IL (1) | IL175933A (ru) |
| LT (1) | LTC1698623I2 (ru) |
| ME (1) | ME02184B (ru) |
| MX (1) | MXPA06007256A (ru) |
| MY (1) | MY139232A (ru) |
| NO (1) | NO339110B1 (ru) |
| NZ (1) | NZ547518A (ru) |
| PL (1) | PL1698623T3 (ru) |
| PT (1) | PT1698623E (ru) |
| RS (1) | RS54033B1 (ru) |
| RU (1) | RU2328489C3 (ru) |
| SI (1) | SI1698623T1 (ru) |
| TW (1) | TW200528432A (ru) |
| WO (1) | WO2005063713A1 (ru) |
| ZA (1) | ZA200605226B (ru) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| ATE508747T1 (de) * | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| EP1683785B1 (en) * | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
| PL1698623T3 (pl) | 2003-12-25 | 2015-08-31 | Eisai R&D Man Co Ltd | Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania |
| US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| WO2006030826A1 (ja) * | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
| KR100951607B1 (ko) * | 2005-06-23 | 2010-04-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 비정질 염 및 그 제조방법 |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN101277720A (zh) * | 2005-09-01 | 2008-10-01 | 卫材R&D管理有限公司 | 崩解性被改善的药物组合物的制备方法 |
| WO2007052849A1 (ja) * | 2005-11-07 | 2007-05-10 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質とc-kitキナーゼ阻害物質との併用 |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| KR20090108086A (ko) * | 2007-01-19 | 2009-10-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 췌장암 치료용 조성물 |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
| DK2387563T4 (da) | 2009-01-16 | 2022-07-18 | Exelixis Inc | Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer |
| US20120077842A1 (en) | 2009-08-19 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| SG187060A1 (en) | 2010-07-16 | 2013-02-28 | Exelixis Inc | C-met modulator pharmaceutical compositions |
| KR20230158644A (ko) | 2011-02-10 | 2023-11-20 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
| CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
| SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102265952B1 (ko) | 2013-06-26 | 2021-06-16 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도 |
| IL302218B2 (en) | 2014-08-28 | 2024-10-01 | Eisai R&D Man Co Ltd | Methods for manufacturing high-purity lenvatinib and its derivatives |
| AU2015311905B2 (en) | 2014-09-03 | 2020-03-05 | Pharmacyclics Llc | Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same |
| JP6792546B2 (ja) * | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体の苦味抑制方法 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| CN106660965A (zh) * | 2015-03-27 | 2017-05-10 | 江苏恒瑞医药股份有限公司 | 乐伐替尼的对甲苯磺酸盐、其结晶形式及制备方法 |
| EP3287444A4 (en) | 2015-05-21 | 2018-09-12 | Crystal Pharmatech Co., Ltd. | New crystal form of lenvatinib methanesulfonate salt and preparation method thereof |
| EP3311841B1 (en) | 2015-06-16 | 2021-07-28 | PRISM BioLab Co., Ltd. | Anticancer agent |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| AU2017249459A1 (en) * | 2016-04-15 | 2018-10-25 | Eisai R&D Management Co., Ltd. | Treatment of renal cell carcinoma with lenvatinib and everolimus |
| CN107305202B (zh) * | 2016-04-22 | 2020-04-17 | 北京睿创康泰医药研究院有限公司 | 分析甲磺酸乐伐替尼及其制剂杂质的hplc方法及杂质作参比标准的用途 |
| CZ2016240A3 (cs) * | 2016-04-27 | 2017-11-08 | Zentiva, K.S. | Soli lenvatinibu |
| CN105801481A (zh) * | 2016-05-20 | 2016-07-27 | 湖南欧亚生物有限公司 | 一种乐伐替尼的合成方法 |
| WO2017221214A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Crystalline forms of salts of lenvatinib |
| WO2017221215A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Salts of lenvatinib |
| EP3299360A1 (en) * | 2016-09-21 | 2018-03-28 | INDENA S.p.A. | Crystal forms of lenvatinib |
| CN106632033A (zh) * | 2016-10-28 | 2017-05-10 | 北京万全德众医药生物技术有限公司 | 乐伐替尼的一种制备方法 |
| BR112019013581A2 (pt) * | 2016-12-29 | 2020-01-07 | Dr. Reddy’S Laboratories Limited | Formas no estado sólido de mesilato de lenvatinibe |
| RU2750539C2 (ru) | 2017-02-08 | 2021-06-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция для лечения опухоли |
| CN109311817B (zh) * | 2017-02-28 | 2022-04-22 | 深圳市塔吉瑞生物医药有限公司 | 取代的含氮芳环化合物及其应用 |
| EP3384901B1 (en) | 2017-04-04 | 2024-08-14 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib mesylate |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| CN110494423B (zh) * | 2017-04-25 | 2022-04-26 | 苏州科睿思制药有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
| AU2018269996A1 (en) | 2017-05-16 | 2019-11-21 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| US11236050B2 (en) | 2017-12-09 | 2022-02-01 | Msn Laboratories Private Limited, R&D Center | Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof |
| CN109988112A (zh) * | 2017-12-29 | 2019-07-09 | 四川科伦药物研究院有限公司 | 仑伐替尼甲磺酸盐的晶型及其制备方法 |
| MA51570A (fr) | 2018-01-10 | 2020-11-18 | Eisai R&D Man Co Ltd | Polythérapies pour le traitement du carcinome hépatocellulaire |
| JP7401460B2 (ja) | 2018-05-14 | 2023-12-19 | メルク・シャープ・アンド・ドーム・エルエルシー | レンバチニブ及びｐｄ－１アンタゴニストを含む組み合わせ療法のためのバイオマーカー |
| CN112204011A (zh) * | 2018-06-01 | 2021-01-08 | 成都苑东生物制药股份有限公司 | 一种甲磺酸乐伐替尼新晶型及其制备方法 |
| CN110845408A (zh) * | 2018-08-20 | 2020-02-28 | 润佳（苏州）医药科技有限公司 | 同位素富集的乐伐替尼 |
| CN110862346A (zh) * | 2018-08-28 | 2020-03-06 | 上海博志研新药物技术有限公司 | 乐伐替尼甲磺酸盐醋酸合物晶型、制备方法及其应用 |
| EP3620453A1 (en) | 2018-09-07 | 2020-03-11 | Indena S.p.A. | New crystal form of lenvatinib |
| EP3632436B1 (en) * | 2018-10-04 | 2022-04-20 | Synthon B.V. | Pharmaceutical composition comprising lenvatinib salts |
| ES2970132T3 (es) * | 2018-10-04 | 2024-05-27 | Synthon Bv | Composición farmacéutica que comprende besilato de lenvatinib |
| WO2020071451A1 (en) | 2018-10-05 | 2020-04-09 | Eisai R&D Management Co., Ltd. | Biomarkers for a therapy comprising a sorafenib compound |
| ES2939143T3 (es) | 2018-10-05 | 2023-04-19 | Eisai R&D Man Co Ltd | Biomarcadores para una politerapia que comprende lenvatinib y everolimus |
| CN111689897B (zh) * | 2019-03-13 | 2024-02-06 | 齐鲁制药有限公司 | 一种高纯度甲磺酸乐伐替尼晶型c的制备方法 |
| CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特（上海）医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
| CN110256341A (zh) * | 2019-06-27 | 2019-09-20 | 尚科生物医药（上海）有限公司 | 一种乐伐替尼甲磺酸盐晶型c的制备方法 |
| CN110229103A (zh) * | 2019-06-27 | 2019-09-13 | 尚科生物医药（上海）有限公司 | 一种乐伐替尼甲磺酸盐晶型b的制备方法 |
| CN112174886A (zh) * | 2019-07-02 | 2021-01-05 | 成都苑东生物制药股份有限公司 | 一种甲磺酸乐伐替尼晶型x的制备方法 |
| MX2022001321A (es) | 2019-08-02 | 2022-05-20 | Akeso Pharmaceuticals Inc | Anticuerpo biespecifico anti-ctla4/anti-pd-1 y uso del mismo. |
| PH12022550211A1 (en) | 2019-08-02 | 2022-12-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anti-pd-1 antibody and medical use thereof |
| CN110563644A (zh) * | 2019-10-30 | 2019-12-13 | 北京赛思源生物医药技术有限公司 | 一种仑伐替尼甲磺酸盐的新晶型 |
| US11059787B2 (en) | 2019-11-12 | 2021-07-13 | Shenzhen Bolan Pharmaceutical Co., Ltd | Crystalline form of lenvatinib mesylate and methods thereof |
| CN111233762B (zh) * | 2020-02-20 | 2021-12-28 | 天津理工大学 | 一种乐伐替尼与对羟基苯甲酸共晶及其制备方法 |
| CN114174264B (zh) * | 2020-04-24 | 2024-02-27 | 成都苑东生物制药股份有限公司 | 一种甲磺酸仑伐替尼晶型xi及其制备方法 |
| CN113999173A (zh) * | 2020-07-28 | 2022-02-01 | 药源药物化学（上海）有限公司 | 一种高纯度结晶的制备方法 |
| CN111793027B (zh) * | 2020-08-07 | 2021-12-03 | 天津理工大学 | 一种乐伐替尼与苯甲酸的共晶及其制备方法 |
| CN116410133A (zh) * | 2021-12-29 | 2023-07-11 | 重庆医药工业研究院有限责任公司 | 一种氟伐替尼氢溴酸盐及其制备方法 |
| CN115710225B (zh) * | 2022-12-08 | 2025-05-23 | 郑州德迈药业有限公司 | 一种仑伐替尼甲磺酸盐的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339136C (en) | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
| JP2517424Y2 (ja) | 1987-07-30 | 1996-11-20 | 株式会社 ナブコ | ポンプ装置 |
| RU2256654C2 (ru) * | 1999-01-22 | 2005-07-20 | Кирин Бир Кабусики Кайся | Хинолиновые и хиназолиновые производные |
| JP2001131071A (ja) | 1999-10-29 | 2001-05-15 | Meiji Seika Kaisha Ltd | 非晶質および非晶質を含有する医薬組成物 |
| WO2002032872A1 (fr) * | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| GB0119467D0 (en) | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
| AU2003280599A1 (en) * | 2002-10-29 | 2004-05-25 | Kirin Beer Kabushiki Kaisha | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| WO2004101526A1 (ja) * | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | ４－（３－クロロ－４－（シクロプロピルアミノカルボニル）アミノフェノキシ）－７－メトキシ－６－キノリンカルボキサミドの多形結晶及びその製造方法 |
| EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
| PL1698623T3 (pl) | 2003-12-25 | 2015-08-31 | Eisai R&D Man Co Ltd | Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania |
| WO2006030826A1 (ja) * | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
-
2004
- 2004-12-22 PL PL04807580T patent/PL1698623T3/pl unknown
- 2004-12-22 SI SI200432247T patent/SI1698623T1/sl unknown
- 2004-12-22 PT PT48075808T patent/PT1698623E/pt unknown
- 2004-12-22 ME MEP-2015-91A patent/ME02184B/me unknown
- 2004-12-22 RU RU2006126977A patent/RU2328489C3/ru active Protection Beyond IP Right Term
- 2004-12-22 HU HUE04807580A patent/HUE025742T2/hu unknown
- 2004-12-22 WO PCT/JP2004/019223 patent/WO2005063713A1/ja not_active Ceased
- 2004-12-22 NZ NZ547518A patent/NZ547518A/en not_active IP Right Cessation
- 2004-12-22 KR KR1020087005282A patent/KR100839554B1/ko not_active Expired - Lifetime
- 2004-12-22 CN CN2008101456016A patent/CN101337932B/zh not_active Expired - Lifetime
- 2004-12-22 EP EP12195436A patent/EP2567955A3/en not_active Withdrawn
- 2004-12-22 AU AU2004309217A patent/AU2004309217B2/en active Active
- 2004-12-22 US US10/577,531 patent/US7612208B2/en active Active
- 2004-12-22 KR KR1020077022490A patent/KR100870681B1/ko not_active Expired - Lifetime
- 2004-12-22 KR KR1020067013993A patent/KR100804566B1/ko not_active Expired - Lifetime
- 2004-12-22 MX MXPA06007256A patent/MXPA06007256A/es active IP Right Grant
- 2004-12-22 JP JP2005516605A patent/JP4648835B2/ja not_active Expired - Lifetime
- 2004-12-22 HR HRP20150694TT patent/HRP20150694T1/hr unknown
- 2004-12-22 CN CNB2004800361841A patent/CN100569753C/zh not_active Ceased
- 2004-12-22 DK DK04807580.8T patent/DK1698623T3/da active
- 2004-12-22 RS RS20150401A patent/RS54033B1/sr unknown
- 2004-12-22 BR BRPI0418200-6A patent/BRPI0418200A/pt not_active Application Discontinuation
- 2004-12-22 CN CN2008101456020A patent/CN101337933B/zh not_active Expired - Lifetime
- 2004-12-22 EP EP04807580.8A patent/EP1698623B1/en not_active Expired - Lifetime
- 2004-12-22 ES ES04807580.8T patent/ES2540852T3/es not_active Expired - Lifetime
- 2004-12-22 CN CN2008101456001A patent/CN101337931B/zh not_active Expired - Lifetime
- 2004-12-22 CA CA2543650A patent/CA2543650C/en not_active Expired - Lifetime
- 2004-12-24 TW TW093140605A patent/TW200528432A/zh unknown
- 2004-12-24 MY MYPI20045373A patent/MY139232A/en unknown
-
2006
- 2006-05-25 IL IL175933A patent/IL175933A/en active IP Right Grant
- 2006-06-23 ZA ZA200605226A patent/ZA200605226B/en unknown
- 2006-07-21 NO NO20063383A patent/NO339110B1/no unknown
-
2010
- 2010-09-01 JP JP2010196072A patent/JP2010280713A/ja not_active Withdrawn
-
2015
- 2015-05-18 CY CY20151100447T patent/CY1116312T1/el unknown
- 2015-10-28 LT LTPA2015039C patent/LTC1698623I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2328489C3 (ru) | Кристаллическая форма соли 4-(3-хлор-4-(циклопропиламинокарбонил)аминофенокси)-7-метокси-6-хинолинкарбоксамида или сольвата этой соли и способы ее получения | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| JP2016065042A5 (ru) | ||
| JP2005521713A5 (ru) | ||
| RU2012138892A (ru) | СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА | |
| WO2005044192A3 (en) | Triazole compounds and uses related thereto | |
| EP1818325A3 (en) | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | |
| Kotb et al. | Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents | |
| JP2014526498A5 (ru) | ||
| JP2013522232A5 (ru) | ||
| NO20074360L (no) | Behandling av metastaterte tumorer | |
| JP2013503134A5 (ru) | ||
| NO20033910D0 (no) | Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin | |
| PE20030923A1 (es) | Forma polimorfica cristalina de clorhidrato de irinotecan | |
| JP2006502115A5 (ru) | ||
| JP2016204373A5 (ru) | ||
| JP2011515421A5 (ru) | ||
| PE20060947A1 (es) | Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion | |
| RU2006120422A (ru) | Новое соединение, соответствующие композиции, способы получения и/или способы лечения | |
| RU2003138078A (ru) | Имидазотриазиноновые производные и их применение против воспалительных процессов и/или иммунных заболеваний | |
| WO2002098399A3 (en) | Cancer treatment method and compositions comprising compounds of the ginger family | |
| RU2019101109A (ru) | Твердые формы ингибитора ttk | |
| TW200724137A (en) | Cancer treatment | |
| Quamruzzaman et al. | Structure− Guided Optimization of Niclosamide Derivatives as Direct STAT3 Inhibitors Targeting a Novel Binding Site | |
| JP2008115173A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RZ4A | Other changes in the information about an invention | ||
| ND4A | Extension of patent duration |
Effective date: 20180601 |